中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

交易中 08-21 15:40:43

5.605

+0.215

+3.99%

最高5.635	最低5.310	成交量1.25亿
今开5.365	昨收5.390	日振幅6.03%
总市值1,047亿	流通市值1,047亿	总股本186.83亿
成交额6.91亿	换手率0.67%	流通股本186.83亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":5.605,"timestamp":1787298042127,"preClose":5.39,"halted":0,"volume":124532580,"delay":0,"changeRate":0.03988868274582574,"floatShares":18683000000,"shares":18683000000,"eps":0.15145048519703316,"marketStatus":"交易中","change":0.215,"latestTime":"08-21 15:40:43","open":5.365,"high":5.635,"low":5.31,"amount":691439348,"amplitude":0.060297,"askPrice":5.61,"askSize":366000,"bidPrice":5.605,"bidSize":517000,"shortable":3,"etf":0,"ttmEps":0.1543208323767857,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787299800000},"marketStatusCode":2,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":5.39,"dividendRate":0.021825,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":1.1659,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.5209,"impliedVolPercentile":0.7959},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2661250346","title":"美银证券：上调中生制药(01177.HK)目标价至7.1港元 重申“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2661250346","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661250346?lang=zh_cn&edition=full","pubTime":"2026-08-21 14:35","pubTimestamp":1787294120,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ08YS42.EUR","BK1515","IE00BZ08YR35.GBP","BK1521","01177","BK1574","01477","BK1191","BK1589","HK0000165453.HKD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109737089","title":"异动解读｜中国生物制药盘中上涨3.15%，中期业绩超预期叠加全球化战略升级","url":"https://stock-news.laohu8.com/highlight/detail?id=1109737089","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109737089?lang=zh_cn&edition=full","pubTime":"2026-08-21 10:29","pubTimestamp":1787279358,"startTime":"0","endTime":"0","summary":"8月21日，中国生物制药盘中上涨3.15%，报5.56港元，成交额2.25亿港元，延续中报发布后的强势表现。创新药及对外授权总收入87.9亿元，同比增长44.3%，占总收入比例升至45.2%。毛利率提升至83.0%，费用率大幅优化。公司同步发布全球新品牌SBP Group，并宣布中期股息每股0.07港元，较去年同期提升40%。管理层预期全年创新药收入占比将达约50%，未来五年将推出30多款创新药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药盘中上涨，创新药收入占比提升","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661259808","title":"大行评级丨大和：上调中国生物制药目标价至7.2港元，重申“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2661259808","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661259808?lang=zh_cn&edition=full","pubTime":"2026-08-21 10:28","pubTimestamp":1787279332,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BZ08YS42.EUR","BK1515","BK1589","01177","BK1521","BK1191","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661255331","title":"【券商聚焦】交银国际维持中国生物制药（01177）买入评级 指差异化管线和AI布局共驱估值修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2661255331","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661255331?lang=zh_cn&edition=full","pubTime":"2026-08-21 08:53","pubTimestamp":1787273599,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，中国生物制药 1H26收入同比增长10.6%至194亿元，其中产品销售收入增长5.6%，主要由创新药驱动，其对总收入的贡献提升至40.2%。经调整净利润大增92%至33亿元，超该机构和市场的预期。毛利率进一步提升至83.0%，SG&A和研发费用率大幅降低至32.0%/17.0%。该机构基于DCF模型得到最新目标价10港元，维持买入评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988913","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","VTHR","CHAT","CZA","LCO","QTOC","AGIX","01177","NIFE","AIPO","REVS","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660023238","title":"【生物医药小白投研】第一篇：打破认知盲区，建立底层框架","url":"https://stock-news.laohu8.com/highlight/detail?id=2660023238","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660023238?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:30","pubTimestamp":1787214600,"startTime":"0","endTime":"0","summary":"生物医药是A股和港股中最特殊的赛道，没有之一。本篇旨在帮助读者打破固有思维，搭建生物医药投资的底层认知框架，为后续的选择、排雷、交易体系打好基础。康方生物：2025年商业化产品销售收入30.33亿元，同比增长51.48%。目前该公司已有4款产品获批上市。典型案例是2026年ASCO期间，康方生物和信达生物等发布了重磅临床数据，但当日股价表现平平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650513943&idx=1&sn=7cbba7ab46d98a94d953d8e9b60809e2&chksm=f30e7cf71bc535c0c64240524852e4b36187629cca446e9bd382f04ea70a74b68d1ffd38d5ce&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU0561508036.HKD","IE00B5MMRT66.SGD","LU0348735423.USD","LU1226287529.USD","IE00BZ08YR35.GBP","LU2097828805.USD","SG9999004220.SGD","LU0501845795.SGD","LU2328871848.SGD","01093","LU0140636845.USD","BK1583","IE00B031HY20.USD","LU1951186391.HKD","LU1720050803.USD","IE0008368742.USD","LU0880133367.SGD","LU1152091168.USD","LU2097828474.EUR","LU0244354667.USD","LU0326950275.SGD","LU0540923850.HKD","06990","KURE","02396","LU0348767384.USD","01177","01801","06872","LU2039709279.SGD","LU1226287875.USD","LU0463099449.HKD","09939","LU2097828557.USD","LU2242644610.SGD","BK1521","LU0348783233.USD","LU0634319403.HKD","LU2097828631.EUR","LU0067412154.USD","LU2097828714.EUR","IE00BZ08YS42.EUR","LU2488822045.USD","LU1226287792.SGD","LU1328277881.USD","03692","LU2778985437.USD","IE0008369823.USD","09926","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660401689","title":"花旗：中国生物制药(01177)中期盈利远超预期 目标价上调至10.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660401689","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660401689?lang=zh_cn&edition=full","pubTime":"2026-08-20 15:22","pubTimestamp":1787210533,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，维持中国生物制药(01177)“买入”评级，目标价由10港元上调至10.8港元。中生制药公布上半年业绩，期内纯利同比增长1.4%至34.4亿元人民币，显著高于市场及该行预期。上半年收入同比增长10.6%至194.4亿元人民币，亦优于该行及市场预期，主要受惠于创新药销售强劲增长44.3%至87.9亿元人民币，管理层预期全年创新药收入占比将达约50%。花旗指出，若剔除2025年上半年来自科兴中维的13.5亿元人民币税后股息，经调整纯利同比大幅增长92.3%。集团管理层预期，2026至2030年间将推出30多款创新药，国内高峰销售潜力达500亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482520.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660401682","title":"花旗：中国生物制药(01177.HK)中期盈利远超预期 目标价上调至10.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660401682","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660401682?lang=zh_cn&edition=full","pubTime":"2026-08-20 15:22","pubTimestamp":1787210533,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ08YS42.EUR","BK1515","BK1589","01177","BK1521","BK1191","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660944408","title":"港股早盘反复扬升 恒指半日涨1.14% 中国生物制药（01177）涨16.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660944408","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660944408?lang=zh_cn&edition=full","pubTime":"2026-08-20 12:11","pubTimestamp":1787199118,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股早盘反复扬升，截至午间收盘，恒指涨1.14%，国企指数涨1.42%，恒生科技指数涨1.54%。中国生物制药涨16.18%，石药集团涨13.47%，老铺黄金涨11.39%，周大福涨7.18%，药明生物涨6.47%。毛利率预计由2025年的55%下降至2026年的51%，经调整净利润率亦由14.5%大幅降至7%，相当于约95亿元人民币。海丰国际半日涨6.02%。详细来看，今年上半年归属于上市公司股东的净利润17.12亿元，同比增长2.44%；基本每股收益1.25元。期内实现营业收入130.71亿元，同比增长7.01%。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988792","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034224299.USD","LU2351347302.SGD","LU1688375341.USD","LU0823426480.USD","LU0315179316.USD","LU2242644610.SGD","LU1366334578.USD","LU0052756011.USD","LU0359201885.HKD","BK1602","BK1541","BOAT","HK0000320264.USD","LU0211977185.USD","LU0862451837.USD","BK1544","LU0328353924.USD","LU2476274308.USD","BK1207","LU0244354667.USD","LU0516423174.USD","LU1235295612.USD","01877","688180","80291","07552","BK1516","LU0572944931.SGD","LU1251922891.USD","LU1719994722.HKD","LU0890818403.SGD","LU1242518857.USD","LU1969619763.USD","LU0417516571.SGD","513600","IE00BYTNYN87.SGD","DRGN","BK1570","LU0417516902.SGD","LU1008478684.HKD","LU1794554557.SGD","LU0348783233.USD","01093","80992","LU0348825331.USD","BK1604","BK1545","BK1103","CJEWY","LU0314109678.HKD","IE00B12V2V27.USD","LU0359201612.USD","02800","BK1151","LU1226287875.USD","HHImain","LU0210526637.USD","IE0003895053.USD","LU0672654166.SGD","CRHKY","IE00B29SXG58.USD","LU2039709279.SGD","LU2097828557.USD","LU2399975544.HKD","SGXZ90724238.SGD","LU1152091754.HKD","LU1720050803.USD","LU1046422090.SGD","01548","SG9999001069.SGD","SG9999011746.SGD","LU0320764599.SGD","LU1769817096.USD","BK1576","LU2097828805.USD","SG9999002463.SGD","LU2097828631.EUR","LU0051755006.USD","BK1141","KURE","09626","BK1224","BK1510","LU0310800965.SGD","LU0516422952.EUR","BK1193","BK1583","BK1578","BK1615","LU0634319403.HKD","BK1171","LU0463099449.HKD","LU1770034418.SGD","LU1951186391.HKD","IE00B0169L03.USD","IE0008369823.USD","03898","HEGIY","LU0029874061.USD","01024","LU2929501877.USD","WXXWY","ZTO","BK1191","LU0348827113.USD","LU0128522157.USD","09115","IE00BYQNZ168.SGD","02013","LU0049112450.USD","LU0320764755.SGD","03419","IE00BZ08YR35.GBP","HSTECH","LU0359202008.SGD","LU0456827905.SGD","LU1152091168.USD","LU1267930227.SGD","HK0000306685.HKD","LU2187417386.USD","LU2097828714.EUR","SG9999003461.SGD","81024","BK1104","BK1161","IE00BZ08YS42.EUR","LU0516422366.SGD","BK1610","BK1574","BK1590","LU0043850808.USD","HK0000320223.HKD","09088","02057","00992","300347","LU0264606111.USD","LU1880383366.USD","IE0003851619.USD","01044","LU2778985437.USD","LU0819121731.USD","BK1500","LNVGY","LU1328615791.USD","LU0128526141.USD","IE0008368742.USD","LU0979878070.USD","IE00BZ08YT58.USD","LU0039217434.USD","LU1226288253.USD","KSTmain","HK0000165453.HKD","SG9999006597.SGD","688331","LU0029875118.USD","LU1171460220.USD","LU1303224171.USD","LU0307460666.USD","LU0791591158.USD","BK1591","BK1180","SG9999014674.SGD","BK1109","IE00B543WZ88.USD","LU1366334651.USD","LU0540923850.HKD","07500","LU0543330483.HKD","LU0417516738.SGD","LU0348784397.USD","03423","MCHmain","LU1961090484.USD","LU0067412154.USD","09926","LU1993786604.SGD","09995","HK0000306701.USD","LU0052750758.USD","LU0501845795.SGD","BK1515","BK1608","HSI","IE0031814852.USD","02269","09067","LU0823426308.USD","BK1116","TCHI","03032","03347","LU3063872942.SGD","SG9999004220.SGD","IE0032431581.USD","LU0516422440.USD","LU1023057109.AUD","02833","IE00BPRC5H50.USD","LU0128525689.USD","07300","LU1226287529.USD","LU2279858448.HKD","BK1518","BK1526","LU1188198961.HKD","07200","00291","LU0862451753.SGD","LU0561508036.HKD","SG9999001093.SGD","LU0516423091.SGD","SOCL","LU2476274720.SGD","LU0348766576.USD","BK1095","IE00B5MMRT66.SGD","LU2097828474.EUR","83115","LU0348735423.USD","BK1618","82800","LU2328871848.SGD","LU1328277881.USD","LU0708995583.HKD","SG9999002562.SGD","LU0072913022.USD","07226","LU1226287792.SGD","BK1565","LU0348767384.USD","03067","HK0000288784.HKD","LU0880133367.SGD","06181","LU0588546209.SGD","LU1813983027.USD","BILI","LU0327786744.USD","LU1807302812.USD","LU0140636845.USD","LU0572939691.SGD","SEA","BK1502","03417","LU2488822045.USD","LU1242518931.SGD","LU1769817179.HKD","LU0456846285.SGD","IE00B031HY20.USD","BK1587","IE0003795394.USD","LU0791590937.USD","IE00B0JY6N72.USD","LU0572940350.SGD","01929","BK1521","LU1226288170.HKD","LU0370786039.SGD","02696","LU0048580855.USD","LU0181495838.USD","01177","BK1588","03033","BK1575","LU0856984785.SGD","LU0326950275.SGD","BK1607","688187","BK1589","01308","SG9999006514.SGD","LU0593848301.USD","03088","BK1227","03115","03037","HK0000288743.USD","02837","BK1601","SG9999001051.SGD","LU1960683339.HKD","SBHMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660408367","title":"中国生物制药股价大涨超过20%，对外授权交易给公司创收了","url":"https://stock-news.laohu8.com/highlight/detail?id=2660408367","media":"第一财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660408367?lang=zh_cn&edition=full","pubTime":"2026-08-20 11:44","pubTimestamp":1787197440,"startTime":"0","endTime":"0","summary":"8月20日上午，中国生物制药（01177.HK）股价开盘后出现大涨，截至9点59分之际，涨幅已超过20%。前一晚，中国生物制药发布的半年报显示：2026年上半年，公司实现收入194.4亿元，同比增长10.6%；归母净利润（基本溢利）达到33.4亿元，剔除非经营影响同比增幅达92.3%。从这份业绩看，创新药的对外授权交易开始在给公司创收了。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847563819.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847563819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01177","BK1589","HK0000165453.HKD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1515","BK1521","IE00BZ08YR35.GBP","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162366260","title":"港股创新药概念股集体走强，中国生物制药涨超20%，石药集团涨超16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162366260","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162366260?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:59","pubTimestamp":1787191169,"startTime":"0","endTime":"0","summary":"8月20日，港股创新药概念股集体走强，$中国生物制药(01177)$涨超20%，$石药集团(01093)$涨超16%，$晶泰控股(02228)$、$金斯瑞生物科技(01548)$涨超12%，$乐普生物(02157)$、$康方生物(09926)$涨超11%，$荣昌生物(09995)$、$复星医药(02196)$涨超7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","LU0634319403.HKD","LU2328871848.SGD","LU1152091754.HKD","LU0348825331.USD","LU1993786604.SGD","09995","IBBQ","BK4588","BK1589","LU0417516571.SGD","IE00BZ08YT58.USD","LU0348827113.USD","LU0326950275.SGD","LU2039709279.SGD","02228","09926","LU1226288253.USD","MEDX","LU0072913022.USD","06978","LU1226288170.HKD","LU0140636845.USD","LU0417516738.SGD","LU1226287529.USD","LU0067412154.USD","02196","BK1593","HK0000306685.HKD","IE0008368742.USD","HK0000320264.USD","LU0417516902.SGD","IE00BZ08YS42.EUR","LU1008478684.HKD","LU0348767384.USD","LU2399975544.HKD","LU1961090484.USD","HK0000306701.USD","BK1141","01093","HK0000320223.HKD","LU0501845795.SGD","LU1951186391.HKD","IE00B5MMRT66.SGD","VXUS","LU1226287792.SGD","LU1807302812.USD","LU1720050803.USD","LU1960683339.HKD","KCAI","BK1521","BK1191","LU1969619763.USD","LU0315179316.USD","SG9999004220.SGD","LU0561508036.HKD","BK1617","01548","LU0880133367.SGD","LU2476274720.SGD","HK0000165453.HKD","BK1515","02157","KURE","LU2488822045.USD","IE0008369823.USD","IE00B031HY20.USD","LU0540923850.HKD","LU0348766576.USD","BK1583","BK4585","BK1576","LU1152091168.USD","IE00BPRC5H50.USD","LU2778985437.USD","LU1813983027.USD","LU1794554557.SGD","BK1161","BK1574","LU2476274308.USD","IE00BZ08YR35.GBP","LU1226287875.USD","LU0348784397.USD","LU0348735423.USD","IE00B543WZ88.USD","159992","LU0314109678.HKD","LU1328277881.USD","LNGR","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160317075","title":"异动解读｜中国生物制药盘中上涨10.33%，中期业绩超预期叠加全球化战略升级","url":"https://stock-news.laohu8.com/highlight/detail?id=1160317075","media":"行情直击","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160317075?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:36","pubTimestamp":1787189760,"startTime":"0","endTime":"0","summary":"8月20日，中国生物制药盘中上涨10.33%，报5.445港元，成交额1.73亿港元。消息面上，公司8月19日发布中期业绩，上半年营收194.4亿元人民币，同比增长10.6%，再创历史新高；经调整归母净利润33.4亿元，同比增长92.3%。其中创新药及对外授权总收入87.9亿元，同比增长44.3%，占总收入比例升至45.2%。同时公司宣布派发中期股息每股0.07港元，较去年同期0.05港元提升40%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药盘中上涨10.33%，中期业绩超预期叠加全球化战略升级","news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660523472","title":"港股异动 | 中国生物制药(01177)绩后高开逾6% 上半年营收达194.4亿元再创新高 持续赢得全球顶级药企背书","url":"https://stock-news.laohu8.com/highlight/detail?id=2660523472","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660523472?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:26","pubTimestamp":1787189211,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药绩后高开逾6%，截至发稿，涨6.05%，报5.08港元，成交额1573.45万港元。消息面上，8月19日，中国生物制药正式公布2026年中期业绩，数据呈现出罕见的高增长态势，不仅营收再创历史新高达到194.4亿元，同比增长10.6%，核心业务经调整归母净利润也实现33.4亿元的稳健增长，同比增速达92.3%。值得一提的是，上半年，中生以源头创新持续赢得全球顶级药企的背书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482386.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","VXUS","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660422810","title":"中国生物制药有限公司发布新的全球品牌SBP Group，加速国际化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422810","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660422810?lang=zh_cn&edition=full","pubTime":"2026-08-19 23:02","pubTimestamp":1787151720,"startTime":"0","endTime":"0","summary":"香港2026年8月19日 /美通社/ -- 中国领先的创新驱动型制药企业中国生物制药有限公司，在中期业绩发布会上宣布推出新的全球品牌SBP Group。统一的品牌形象，体现了公司从国内领先的生物制药企业向全球创新者的战略演进。SBP Group愿联动全球合作伙伴，加速中国创新走向全球、全球创新进入中国的进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5029441_ZH29441_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5029441_ZH29441_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["HK0000165453.HKD","BK1515","BK1191","IE00BZ08YT58.USD","01177","BK1521","IE00BZ08YS42.EUR","BK1589","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660448704","title":"中国生物制药(01177)中报观察：All in AI与全球化双引擎启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2660448704","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660448704?lang=zh_cn&edition=full","pubTime":"2026-08-19 17:16","pubTimestamp":1787130988,"startTime":"0","endTime":"0","summary":"中国生物制药正在进入这样一个关键阶段。在安得卫等战略产品的生产中，AI工具在细胞培养监控与纯化风险评估中的应用，助力抗体产量提高20%，生物药制造成本下降20%，直接拉升了产品毛利。其中bepirovirsen有望成为全球首款获批的乙肝功能性治愈药物，其在B-Well系列三期临床中展现出优异的功能性治愈率。纵观2026年中报，中国生物制药正展现出一种“罕见的活力”。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["QTOC","CHAT","IE00BZ08YS42.EUR","ARTY","VTHR","IE00BZ08YR35.GBP","BK1191","BK1515","BK1521","AGIX","IE00BZ08YT58.USD","AIPO","01177","BK1589","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660493594","title":"中国生物制药（01177）中期股东溢利同比增长1.36% 拟派中期股息7港分","url":"https://stock-news.laohu8.com/highlight/detail?id=2660493594","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660493594?lang=zh_cn&edition=full","pubTime":"2026-08-19 17:02","pubTimestamp":1787130142,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药（01177）公布截至2026年6月30日止六个月业绩，股东应占溢利34.35亿元人民币，同比增长1.36%；每股基本盈利19.10人民币分。董事会宣布派中期股息每股7港分。期内营收194.44亿元人民币，同比增长10.64%。其中，创新药及对外授权总收入87.9亿元，同比增长44.3%，占总收入比例上升至45.2%。研发方面，期内集团研发总投入约3.29亿元，占集团收入约16.9%，其中约93.6%已计入损益表中。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/NzVmNzI2NGE4ZDk3NWFhOTZkNGE5Nzk4MDcyMTM1NjM3MTc0MDU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NzVmNzI2NGE4ZDk3NWFhOTZkNGE5Nzk4MDcyMTM1NjM3MTc0MDU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988737","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIG","BK1589","BK1521","BK4588","BK1515","BK1191","01177","BK4585","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660498904","title":"中国生物制药上半年收入194.4亿元，同比增长10.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660498904","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660498904?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:55","pubTimestamp":1787129700,"startTime":"0","endTime":"0","summary":"8月19日，中国生物制药（01177）发布截至2026年6月30日止6个月的中期业绩公告。报告期内，公司收入194.4亿元，同比增长10.6%；归属于母公司持有者基本溢利33.4亿元，同比增长8.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608193846321537.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608193846321537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BZ08YR35.GBP","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1515","BK1521","01177","BK1589","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135605868","title":"中国生物制药(01177)宣布派发2026年中期股息每股0.07港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135605868","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135605868?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:36","pubTimestamp":1787128578,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司（01177）8月19日公布2026年中期股息方案。董事会决定向截至2026年6月30日止六个月的普通股股东派发每股0.07港元现金股息。此次股息无需股东进一步批准。\n本次派息的除净日为2026年9月1日；股东如欲获派股息，须于2026年9月2日16时30分前将股份过户文件递交至卓佳证券登记有限公司。公司股份过户登记册将于2026年9月3日至9月4日暂停办理过户手续，记录日期为2026年9月4日。\n派息款项预计于2026年9月24日支付。公司披露，本次股息不涉及任何代扣所得税安排。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100481847","title":"财报前瞻｜中国生物制药营收结构稳固，本季度盈利修复待验证","url":"https://stock-news.laohu8.com/highlight/detail?id=1100481847","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100481847?lang=zh_cn&edition=full","pubTime":"2026-08-12 08:21","pubTimestamp":1786494103,"startTime":"0","endTime":"0","summary":"中国生物制药将于2026年08月19日发布最新季度财报，市场关注创新与仿制组合的盈利质量与现金流改善节奏。中国生物制药在普药与特色仿制上具备一定产品线广度，本季度关注新中标品种放量、老品种份额维护与成本费用的协同。中国生物制药在全国范围的医院与零售渠道布局较为完善，本季度的看点在于重点省份放量与新进入医院的铺货深度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜中国生物制药营收结构稳固，本季度盈利修复待验证","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1117797293","title":"异动解读｜中国生物制药盘中上涨3.83%，贝莫苏拜单抗联合安罗替尼肺鳞癌新适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1117797293","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117797293?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:33","pubTimestamp":1786325607,"startTime":"0","endTime":"0","summary":"8月10日，中国生物制药盘中上涨3.83%，报5.23港元，成交额3842.54万港元。消息面上，公司8月7日公告，旗下正大天晴自研的贝莫苏拜单抗注射液联合化疗序贯联合安罗替尼胶囊获NMPA批准上市，用于一线治疗局部晚期或转移性鳞状非小细胞肺癌，为安罗替尼第12个获批适应症、贝莫苏拜单抗第6个获批适应症。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657561034","title":"中国生物制药(01177)：贝莫苏拜单抗联合化疗序贯联合安罗替尼一线治疗鳞状非小细胞肺癌新适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657561034","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657561034?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:00","pubTimestamp":1786100404,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药贝莫苏拜单抗注射液联合化疗序贯联合盐酸安罗替尼胶囊已获得中国国家药品监督管理局的上市批准，用于一线治疗局部晚期或转移性鳞状非小细胞肺癌。这是安罗替尼获批的第12个适应症，是贝莫苏拜单抗获批的第6个适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477456.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","IPOS","BK1521","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1515","BK1191","HK0000165453.HKD","01177","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.1068},{"period":"1month","weight":0.0548},{"period":"3month","weight":0.0444},{"period":"6month","weight":-0.1802},{"period":"1year","weight":-0.2645},{"period":"ytd","weight":-0.1178}],"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.0225},{"period":"3month","weight":0.0036},{"period":"6month","weight":-0.0271},{"period":"1year","weight":0.0212},{"period":"ytd","weight":0.0027}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.007657},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056403},{"month":3,"riseRate":0.565217,"avgChangeRate":0.046203},{"month":4,"riseRate":0.478261,"avgChangeRate":0.020807},{"month":5,"riseRate":0.695652,"avgChangeRate":0.037978},{"month":6,"riseRate":0.347826,"avgChangeRate":0.004739},{"month":7,"riseRate":0.652174,"avgChangeRate":0.052342},{"month":8,"riseRate":0.434783,"avgChangeRate":-0.007053},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.014397},{"month":10,"riseRate":0.545455,"avgChangeRate":0.024699},{"month":11,"riseRate":0.5,"avgChangeRate":0.067223},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.012172}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SBP GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}